Menu
Subscribe - Individual
Subscribe - Biotech Premium (Corporate)
Home
About Us
Subscribe
Subscribe Individual
Subscribe Biotech Premium (Corporate)
Premium Biotech Coverage
Current News
Special Features
Company Index
Index Table
Summit
19th Bioshares Biotech Summit
Summit History
Contact
Contact Us
Email Alerts
Categories
Categories
Actinogen (ACW)
Adalta (1AD)
Amplia Therapeutics (ATX)
Anteris Technologies (AVR)
Aroa Biosurgery (ARX)
Blinklab (BB1)
Blog
Botanix (BOT)
Chimeric Therapeutics (CHM)
Clever Culture Systems (CC5)
Clinuvel Pharmaceuticals (CUV)
Cogstate (CGS)
Dimerix (DXB)
EBR Systems (EBR)
Immuron (IMC)
Imugene (IMU)
Island Pharmaceuticals (ILA)
Neuren Pharmaceuticals (NEU)
Patrys (PAB)
Syntara (SNT) (previously Pharmaxis, PXS)
Uncategorized
October 11th, 2024
Opthea Share Price Starts to Move Ahead of Phase III Trial Readouts Mid-2025
Read More
September 3rd, 2024
What's Next for Clinuvel Pharmaceuticals?
Read More
August 1st, 2024
Island Pharmaceuticals Update
Read More
August 1st, 2024
Summit Coverage: Neuren Pharmaceuticals Outlines Path Forward for NNZ-2591
Read More
August 1st, 2024
Neuren Pharmaceuticals Reports Positive Results in Third Indication - Angelman Syndrome
Read More
August 1st, 2024
Aroa Biosurgery - Moving to Cashflow Positive
Read More
July 10th, 2024
Botanix Raises $70 million with Sofdra FDA Approval
Read More
July 10th, 2024
Island Pharmaceuticals to In-License New Asset
Read More
July 10th, 2024
Clinuvel Pharmaceuticals Continues Expansion of Portfolio into Parkinson's Disease
Read More
July 10th, 2024
Donanemab Approved for Alzheimer's Disease; Positive News for Cogstate
Read More
July 10th, 2024
Radiopharm to Raise $70 Million Following Transformational Lantheus Deal
Read More
June 13th, 2024
Neuren Pharmaceuticals: Positive Phase II Results in Second Study with NNZ-2591
Read More
June 13th, 2024
Anteris Technologies to Seek Nasdaq Listing Ahead of Registration Study
Read More
June 12th, 2024
Second Licensing Deal for Dimerix; Share Price Up 65%
Read More
May 19th, 2024
Blinklab Partners with Autism Foundation for Pre-Registration Study
Read More
April 19th, 2024
IPO Preview – Blinklab
Read More
January 4th, 2024
Top Six Picks for 2024 (Dimerix; ASX = DXB)
Read More
January 4th, 2024
Impressive Results from Neuren's NNZ-2591 Phase II Clinical Trial in Phelan- McDermid Syndrome
Read More
December 12th, 2023
Investor Interest Starts Return to Biotech Sector (Clinuvel)
Read More
December 12th, 2023
Investor Interest Starts Return to Biotech Sector (Dimerix)
Read More
Pages
1
2
3
4
5
6
7
8
9
